|
Efficacy of mogamulizumab in previously treated patients with less advanced mycosis fungoides: Results from the MAVORIC study. |
|
|
Consulting or Advisory Role - Actelion; Kyowa Hakko Kirin; Mallinckrodt; Soligenix |
Research Funding - Helsinn Healthcare; Kyowa Hakko Kirin; Mallinckrodt; Merck |
Travel, Accommodations, Expenses - Kyowa Hakko Kirin |
|
|
Honoraria - 4SC; Kyowa Hakko Kirin; Mallinckrodt; Takeda |
Consulting or Advisory Role - 4SC; Innate Pharma; Kyowa Hakko Kirin; Mallinckrodt; Takeda |
Research Funding - Kyowa Hakko Kirin; Takeda |
|
|
Stock and Other Ownership Interests - Innate Pharma |
Consulting or Advisory Role - Innate Pharma; Kyowa Hakko Kirin; miRagen |
Patents, Royalties, Other Intellectual Property - Innate Pharma |
|
|
Consulting or Advisory Role - Genentech; Gilead Sciences |
|
|
Stock and Other Ownership Interests - Aevi Genomic Medicine (I) |
Consulting or Advisory Role - Leo Pharma |
Research Funding - elorac; Kyowa Hakko Kirin; Soligenix |
Travel, Accommodations, Expenses - Soligenix |
|
|
Research Funding - Seagen |
Travel, Accommodations, Expenses - Kyowa Hakko Kirin |
|
|
Consulting or Advisory Role - Takeda |
Speakers' Bureau - Celgene; Takeda |
|
|
|
Consulting or Advisory Role - Actelion; Galderma; Seagen |
Research Funding - Actelion; Galderma; Kyowa Hakko Kirin; MedImmune; Soligenix |
Travel, Accommodations, Expenses - Actelion; Galderma; Soligenix |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |